Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose Optimization and Expansion Study of BB-1701 in Previously Treated HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
jRCT2031230750Phase 2Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of BB-1701 in breast cancer (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Safety and tolerability of BB-1701 in dose optimization and Efficacy of BB-1701 at recommended dose in dose expansion. Started Apr 2025; status: active, not recruiting.
02
Drugs
BB-1701
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031230750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230750.